Region Hovedstaden

Research site

Denmark Nordre Fasanvej 57, 1st Floor Entrance 2, 2000 Frederiksberg, Denmark

12 trials recruiting
Arteriosclerosis · Obesity · Osteoarthritis
Adult patients

About Specializations

Region Hovedstaden in Frederiksberg, Denmark specialises in clinical trials of conditions such as Arteriosclerosis, Obesity, Osteoarthritis, Overweight, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Nordre Fasanvej 57, 1st Floor Entrance 22000 FrederiksbergDenmark

Open in maps ↗

Recruiting now: 12 trials
Conditions studied: 14

More sites in Frederiksberg Denmark

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

15 clinical trials

Arteriosclerosis

Recruiting

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational

Denmark

Participants:18–64 years · 65+ years
Sponsor:AstraZeneca AB

Contact Research Centre

Arteriosclerosis

Recruiting

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational

Denmark

Participants:18–64 years · 65+ years
Substances:Maridebart Cafraglutide
Sponsor:Amgen Inc.

Contact Research Centre

Atrial fibrillation

Recruiting

Safety and Pharmacodynamics of RBD4059 and Apixaban in Patients with Non‑Valvular Atrial Fibrillation: A Randomized Active‑Controlled Study

Registered drug

Safety and Pharmacodynamics of RBD4059 and Apixaban in Patients with Non‑Valvular Atrial Fibrillation: A Randomized Active‑Controlled Study

Registered drug

Denmark

Participants:18–64 years · 65+ years
Substances:Apixaban
Sponsor:Ribocure Pharmaceuticals AB

Contact Research Centre

Rheumatoid arthritis

Recruiting

Long‑Term Safety and Efficacy of RO7790121 in Adults with Moderate to Severe Rheumatoid Arthritis: Extension Study

Investigational

Long‑Term Safety and Efficacy of RO7790121 in Adults with Moderate to Severe Rheumatoid Arthritis: Extension Study

Investigational

Denmark

Participants:18–64 years · 65+ years
Substances:RO7790121
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Coronary artery disease+1

Recruiting

Study to evaluate if colchicine reduces inflammation in patients with chronic coronary artery disease

Registered drug

Study to evaluate if colchicine reduces inflammation in patients with chronic coronary artery disease

Registered drug

Denmark

Participants:18–64 years · 65+ years
Substances:Colchicine
Sponsor:Rigshospitalet

Contact Research Centre

Cardiac failure+1

Recruiting

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

Denmark

Participants:18–64 years · 65+ years
Sponsor:Novo Nordisk A/S

Contact Research Centre

Obesity+2

Recruiting

A study to evaluate the effects of zenagamtide on weight and pain in patients with overweight or obesity and knee osteoarthritis

Investigational

A study to evaluate the effects of zenagamtide on weight and pain in patients with overweight or obesity and knee osteoarthritis

Investigational

Denmark

Participants:18–64 years · 65+ years
Sponsor:Novo Nordisk A/S

Contact Research Centre

Obesity+2

Recruiting

A study to evaluate the efficacy and safety of zenagamtide in people with overweight or obesity and knee osteoarthritis

Investigational

A study to evaluate the efficacy and safety of zenagamtide in people with overweight or obesity and knee osteoarthritis

Investigational

Denmark

Participants:18–64 years · 65+ years
Sponsor:Novo Nordisk A/S

Contact Research Centre

Drug dependence

Recruiting

Study of semaglutide to reduce cannabis use in adults with cannabis use disorder

Registered drug

Study of semaglutide to reduce cannabis use in adults with cannabis use disorder

Registered drug

Denmark

Participants:18–64 years · 65+ years
Substances:Semaglutide
Sponsor:Region Hovedstaden

Contact Research Centre

Arteriosclerosis

Recruiting

A Study of Olpasiran for Patients With Stable Heart and Blood Vessel Disease and High Lipoprotein(a) to Measure Changes in Artery Plaque Using Heart Scans

Investigational

A Study of Olpasiran for Patients With Stable Heart and Blood Vessel Disease and High Lipoprotein(a) to Measure Changes in Artery Plaque Using Heart Scans

Investigational

Denmark

Participants:18–64 years · 65+ years
Sponsor:Amgen Inc.

Contact Research Centre

Depression

Recruiting

Study of Flumazenil to Reduce Side Effects of Electroconvulsive Therapy in Patients with Depression

Registered drugNo placebo

Study of Flumazenil to Reduce Side Effects of Electroconvulsive Therapy in Patients with Depression

Registered drugNo placebo

Denmark

Participants:18–64 years · 65+ years
Sponsor:Region Hovedstaden

Contact Research Centre

Cardiac failure chronic+1

Recruiting

Study on Ferric Derisomaltose for Patients with Iron Deficiency and Chronic Heart Failure

Registered drugNo placebo

Study on Ferric Derisomaltose for Patients with Iron Deficiency and Chronic Heart Failure

Registered drugNo placebo

Denmark

Participants:18–64 years · 65+ years
Substances:Ferric Derisomaltose
Sponsor:Pharmacosmos A/S

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites